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Likeineverytypeofcancer,inskincancertheeﬃciencyofthemedicaltreatmentisveryimportant.Inthepresentpaper,aBayesian
model for the management of this disease is given, and a medical index to measure the eﬀectiveness of treatment from medical,
economical, and quality of life point of view is presented, taking into account some of the patients characteristics.
1.Introduction
During the last 10–15 years an alarming increase of the
photo-induced cutaneous cancers was registered nationally
and internationally (1.000.000 new cases in 2007 in the
USA), reaching epidemic proportions in some areas. At the
moment, the number of patients with cutaneous cancers has
signiﬁcantly increased in Romania. The real incidence of this
pathology is unknown, partly due to the lack of an integrated
national or regional database. The phenomenon is more
frequent in the case of persons who uncontrollably expose
themselvestoultravioletraysforcosmeticortherapeuticrea-
sonsorduetoimproperworkconditions,withoutprotection
outﬁts, but it depends also on other reasons, as photo type,
age, gender, and so forth. Since we witness a continuous pro-
cess of ozone layer alteration, global warming, and increase
in the pollution degree, the prevention of photo-induced
cutaneous cancers and elaboration of protocols for preco-
cious diagnosis and innovative treatment appear as a priority
issue of public health (see [1]).
One strategy used in medicine to identify and treat a
disease is by screening. Its purpose is to identify in an early
stage some malady in a community, enabling timely inter-
vention and management in order to reduce suﬀering and
mortality. In the speciﬁc case of skin cancer, this strategy
also functions. In order to obtain good results, the measure-
m e n t sh a v et ob et a k e nf r o md i ﬀerent points of view. For
instance, most published researches are based on the study of
cost and eﬀectiveness of a treatment (see [2–6]), taking into
account diﬀerent characteristics of the patients. The present
paper proposes to determine the eﬃciency of the treatment
also from the quality of life point of view. The results are
obtained by means of a Bayesian approach for determining
the involved parameters, and, as a measure, the economical
index is obtained.
2.BayesianRegression Model
We consider a sample of n individuals with melanoma in
diﬀerent stages, participating in a clinical trial and denote
by (Ef i) the eﬀectiveness data, by (Ci) cost data, and by
(Qi) the quality of life for each patient i, i ∈{ 1,...,n}.
These n patients are considered to be split in two diﬀerent
groups: those who are under treatment and those who are
not. The results of the clinical trial, in terms of eﬀectiveness,
costs, and quality of life, are not determined only by the
type of treatment received, and so it is necessary to consi-
der a series of possible covariates that may inﬂuence the
above results. Such covariates include the patient’s photo
type, age, state of health at the time of the clinical trial,
gender, and other characteristics that depend on the type of
clinical trial under analysis. We deﬁne X as an n × (k +1 )
matrix of covariates, where each column (Xi)r e f e r st oo n e
covariate. The ﬁrst column is a column of ones referring to2 Computational and Mathematical Methods in Medicine
the constant (see [7, 8]). We seek, therefore, to explain the
results obtained (Ef i, Ci,a n dQi), as a linear combination
of the k covariates considered (the patient’s individual char-
acteristics and the type of treatment received). For this pur-
pose,weproposeaBayesianmultiplelinearregressionmodel
in which the perturbation terms (ui, vi,a n dwi)a r ea s s u m e d
tobeGaussian,independent,andidenticallydistributedwith
am e a no f0a n dv a r i a n c e so fσ2
1, σ2
2,a n dσ2
3, respective-
ly,
Ef i = β0 +β1 ·X1,i +β2X2,i + ···+βk−1,i +βT,i +ui,
Ci = δ0 +δ1 · X1,i +δ2X2,i + ···+δk−1,i +δT,i +vi,
Qi = q0 + q1 ·X1,i + q2X2,i + ···+ qk−1,i + qT,i +wi,
(1)
where the vectors β=(β0,β1,...,βk−1,βT), δ =(δ0,δ1,...,
δk−1,δT), q=(q0,q1,...,qk−1,qT), and the accuracy values
τ1 =σ
−2
1 , τ2 =σ
−2
2 , τ3 =σ
−2
3 are the parameters of the model.
The k covariates considered for which data are available
need not to be explicative of the eﬀectiveness, the costs, and
the quality of life, and so the above general model could be
corrected by eliminating those covariates that do not explain
eﬀectiveness and cost.
The ﬁrst step to be taken in estimating the parameters is
to determine the likelihood function of eﬀectiveness le(Ef |
β,τ1), lc(C | δ,τ2), lq(Q | q,τ3), where Ef = (Ef1,...,Efn),
C = (C1, ...,Cn), and Q = (Q1,... ,Qn). In this stage both
costs,eﬀectivenessandqualitiesoflifeareassumedtopresent
a normal distribution, and so the likelihood functions are
represented by the following expressions:
l

Ef,C,Q | β,δ,q,τ1,τ2,τ3

= le

Ef | β,τ1

· lc(C | δ,τ2) · lq

Q | q,τ3

,
(2)
where
le

Ef | β,τ1

∝ τN/2
1 ·exp

τ1
2

Ef −Xβ
 
Ef −Xβ

,
lc(C | δ,τ2) ∝ τN/2
2 · exp

τ2
2
(C − Xδ)
 (C − Xδ)

,
lq

Q | q,τ3

∝ τN/2
3 · exp

τ3
2

Q −Xq
 
Q −Xq

.
(3)
Assuming model (1) from a Bayesian point of view, we must
specifythepriordistributionforthe3·k+6parametersofthe
model. The prior distribution represents expert information
about the set of model parameters before the sample obser-
vations are analysed. We propose a normal (N), respect-
ively, gamma (G) form for the base prior and assume inde-
pendencebetweenthecoeﬃcientsβ,δ, q andprecisionterms
τ1, τ2, τ3. Therefore,
π

β,τ1

= πe,1

β

·πe,2(τ1),
π(δ,τ2) = πc,1(δ) ·πc,2(τ2),
π

q,τ1

= πq,1

q

·πq,2(τ3),
(4)
where
πe,1

β

≈ N

β0,V
−1
1

, πc,1(δ) ≈ N

δ0,V
−1
2

,
πq,1

q

≈ N

q0,V−1
3

,
πe,2(τ1) ≈ G(a1,b1), πc,2(τ2) ≈ G(a2,b2),
πq,2(τ3) ≈ G(a3,b3).
(5)
The parameters β0, V1, δ0, V2, q0, V3, a1, b1, a2, b2, a3, b3,
which determine the prior distribution, are deﬁned on the
basis of the initial information (available when the analysis
begins). The joint posterior distribution of the parameters β,
δ, q, τ1, τ2, τ3, given the data (Ef,C,Q), can be calculated
from (4), using Bayes’ theorem
π

β,τ1 | Ef

∝ τ
(n+2a1)/2−1
1
· exp

−
1
2

Ef −Xβ
 
Ef −Xβ

+

β −β0

V
−1
1

β −β0

+2 b1τ1

,
π(δ,τ2 | C) ∝ τ
(n+2a2)/2−1
2
· exp

−
1
2

(C −Xδ)
 (C −Xδ)
+(δ −δ0)V−1
2 (δ −δ0)+2 b2τ2

,
π

q,τ3 | Q

∝ τ
(n+2a3)/2−1
3
· exp

−
1
2

Q −Xq
 
Q − Xq

+

q − q0

V−1
3

q − q0

+2b3τ3

.
(6)
Inferencesaboutquantitiesofinterestmustbebasedonthese
posterior distributions. The prior distributions used here are
not the only possible choices.
3.The Medicoeconomical Evaluation
The standard measure used to compare only the cost and ef-
fectiveness of treatments is the incremental cost-eﬀectiveness
ratio (ICER). Nevertheless, this measure presents severe in-
terpretational problems, as well as diﬃculties in estimating
the conﬁdence or credibility intervals. The incremental net
beneﬁt (INB) has been proposed as an alternative to ICER
(see [8]). The INB of treatment 1 (new) versus treatment 0
(actual or control) is deﬁned as
INB(Rc) = Rc

μ1 −μ2

−(ν1 −ν2),( 7 )
where μ’s and ν’s are the mean eﬀectiveness and cost of
the respective treatments. The value Rc is interpreted as the
cost that decision-makers are willing to accept in order to
increase the eﬀectiveness of the treatment applied by one
unit. Thus, analyzing whether the alternative treatment isComputational and Mathematical Methods in Medicine 3
more cost eﬀective than the control treatment is equivalent
to determining whether INB(Rc)i sp o s i t i v e .
For our problem, we use the medicoeconomical index
denoted by MEI(λe,λc,λq) introduced in [3], according to
MEI

λe,λc,λq
	
= λe

μ1 −μ0

+λc(ν1 −ν0)+λq

γ1 −γ0

,
(8)
where μ’s, ν’s, and γ’s are the mean eﬀectiveness, cost, and
quality of life of the respective treatments. The values λe, λc,
and λq are weights (0 ≤ λe ≤ 1, 0 ≤ λc ≤ 1, 0 ≤ λq ≤ 1,
λq + λq + λq = 1) which reﬂect the importance we give to
each criteria (the medication eﬀect, the medication costs, the
quality of life).
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